User:Fvasconcellos/monoclonalschecklist


 * This is a list compiled from, meant to assess the verifiability of all articles in the category.

A

 * Abagovomab multiple studies
 * Adecatumumab multiple studies
 * Afelimomab multiple studies
 * Afutuzumab INN, USAN, no PubMed hits
 * Alacizumab pegol INN, no PubMed hits
 * Altumomab one study
 * Ananeuzumab putative USAN
 * Anatumomab mafenatox rINN, in phase II trials
 * Anergrozumab putative USAN
 * Anetumumab putative USAN for zalutumumab
 * Anrulizumab
 * Apolizumab multiple studies
 * Arcitumomab multiple studies
 * Aselizumab rINN, in phase II trials
 * Atlizumab multiple studies
 * Atorolimumab rINN, but no PubMed results
 * Azulizumab

B

 * Balizumab putative USAN
 * Bapineuzumab USAN, in phase III trials
 * Basiliximab in clinical use
 * Bavituximab one study, in open label trials
 * Bectumomab one study
 * Belizumab putative USAN
 * Bertilimumab rINN, in phase II trials
 * Betumumab putative USAN
 * Biciromab brallobarbital INN
 * Bivatuzumab mertansine rINN, multiple studies
 * Blinatumomab USAN

C

 * Canakinumab INN, one study
 * Cantuzumab mertansine rINN, multiple studies
 * Capromab pendetide in clinical use since 1996
 * Catumaxomab rINN, in phase II/III studies
 * Cedelizumab INN, but no studies
 * Cetforlimumab
 * Cetinlimumab
 * Cetlalimumab
 * Cetolimumab
 * Cidfusituzumab
 * Cidtuzumab
 * Citatuzumab bogatox INN, no PubMed hits
 * Citilimumab
 * Cixutumumab USAN, no PubMed hits
 * Clenoliximab INN, multiple studies
 * Conatumumab USAN, no PubMed hits
 * Cynosumab

D

 * Dacetuzumab USAN of SG-40
 * Denosumab rINN, multiple studies
 * Destilimumab
 * Detumomab INN
 * Doraglizumab putative USAN
 * Dorlimomab aritox INN
 * Dorlixizumab suggested USAN
 * Dorlizumab putative USAN
 * Drimakinzumab USAN under consideration
 * Drinalizumab putative USAN
 * Duntumumab putative USAN of zalutumumab
 * Durimulumab putative USAN of stamulumab
 * Durlizumab putative USAN
 * Durmulumab putative USAN of stamulumab

E

 * Ecromeximab rINN/USAN; ; nothing in PubMed
 * Edobacomab multiple studies
 * Efalizumab in clinical use
 * Efungumab rINN, multiple studies, twice denied approval by EMEA
 * Elsilimomab INN, in phase II trials
 * Epitumomab cituxetan rINN,
 * Epkizumab
 * Epratuzumab multiple studies
 * Erlizumab rINN,
 * Ertumaxomab one published study, in phase II trials
 * Etaracizumab suggested USAN, phase I trials completed
 * Exbivirumab rINN, ; nothing in PubMed
 * Extumumab putative USAN

F

 * Fanolesomab in clinical use (diagnostic agent)
 * Faralimomab INN
 * Farletuzumab USAN, Phase I/II studies, no PubMed hits
 * Felvizumab INN
 * Figitumumab USAN, no PubMed hits
 * Fontolizumab multiple studies; structure deposited in PDB
 * Foravirumab INN, no PubMed hits
 * Futumumab putative USAN

G

 * Galiximab multiple studies, in phase III trials
 * Gantenerumab rINN
 * Gavilimomab rINN, two studies
 * Gemtuzumab ozogamicin in clinical use
 * Genosumab
 * Ginakinzumab USAN under consideration
 * Golimumab multiple studies, in phase III trials
 * Gomiliximab USAN

H

 * Hylizumab putative USAN

I

 * Ibalizumab one study
 * Igovomab INN (diagnostic agent)
 * Imciromab multiple studies, in clinical use
 * Inolimomab multiple studies
 * Inotuzumab ozogamicin multiple studies
 * Intumumab putative USAN
 * Ipilimumab rINN, multiple studies
 * Iratumumab rINN/USAN
 * Ixutumumab USAN under consideration

K

 * Keliximab rINN, multiple studies

L

 * Labetuzumab INN, multiple studies
 * Lebrilizumab USAN under consideration
 * Lemalesomab INN
 * Lerdelimumab INN, multiple studies
 * Lexatumumab INN, multiple studies
 * Libivirumab INN
 * Lintuzumab INN, multiple studies
 * Lucalizumab
 * Lucatumumab USAN
 * Lumiliximab INN, multiple studies

M

 * Mapatumumab INN, multiple studies
 * Maslimomab INN
 * Matenazumab purported USAN
 * Matuzumab INN, in phase II trials
 * Mepolizumab INN, multiple studies
 * Metelimumab INN, in phase II trials
 * Milatuzumab USAN, in Phase I/II studies, 1 report in PubMed
 * Minretumomab INN
 * Mitumomab INN, in phase III trials
 * Morolimumab INN
 * Motavizumab INN, multiple studies
 * Muromonab-CD3 in clinical use

N

 * Nacolomab tafenatox INN
 * Naptumomab estafenatox INN
 * Nebacumab INN, multiple studies
 * Necitumumab INN
 * Nerelimomab INN, one study in PubMed
 * Neutrospec trade name of 99m-Tc fanolesomab
 * Nimotuzumab INN, multiple studies
 * Nofetumomab merpentan diagnostic agent, multiple studies
 * Nolovizumab
 * Numavizumab purported USAN

O

 * Ocrelizumab INN, in phase III trials
 * Odulimomab INN, multiple studies
 * Ofatumumab rINN, phase I/II trial results published
 * Oportuzumab monatox INN
 * Oregovomab INN, multiple trials ongoing
 * Oteliximab
 * Otelixizumab USAN, news story

P

 * Pagibaximab INN,
 * Palivizumab in clinical use
 * Panobacumab INN
 * Pascolizumab INN, two PubMed hits
 * Pecfusituzumab
 * Pectuzumab
 * Pemtumomab multiple studies, in phase III trials
 * Pexelizumab pINN, multiple studies
 * Pintumomab move to INN (technetium (99mTc) pintumomab)
 * Priliximab one study
 * Pritumumab INN

Q

 * Quartuzumab
 * Quetumumab

R

 * Rafivirumab INN, no PubMed hits
 * Ralivizumab
 * Ramucirumab USAN, no PubMed hits
 * Raxibacumab USAN,
 * Regavirumab INN, three reports in PubMed
 * Resatumumab
 * Reslivizumab purported USAN
 * Reslizumab INN/USAN, multiple studies
 * Restumumab purported USAN
 * Resyvizumab purported USAN
 * Rilotumumab USAN
 * Robatumumab INN, USAN
 * Rosutumumab
 * Rovelizumab INN,
 * Ruplizumab INN,

S

 * Satumomab pendetide diagnostic agent, in clinical use; INN is satumomab
 * Sevirumab INN, multiple studies
 * Sibrotuzumab INN, multiple studies
 * Siltuximab INN
 * Siplizumab INN, three PubMed hits
 * Sonepcizumab
 * Sontuzumab INN
 * Stamulumab INN, two PubMed hits
 * Stolanezumab USAN under consideration
 * Sulesomab INN, in clinical use
 * Synosumab

T

 * Tacatuzumab tetraxetan--in SciFinder CAS#476413-07-7
 * Tadocizumab--in SciFinder CAS#339086-80-5
 * Talineuzumab--not in PubMed or SciFinder
 * Talizumab--in PubMed
 * Taneuzumab--not in PubMed or SciFinder
 * Tanezumab--USAN, in PubMed
 * Tanirazumab--not in PubMed or SciFinder
 * Taplitumomab paptox--in SciFinder CAS#235428-87-2
 * Tefibazumab--in PubMed
 * Teglizumab--not in PubMed or SciFinder
 * Telimomab aritox--in SciFinder CAS#117305-33-6
 * Tenatumomab--INN, not in PubMed
 * Teneliximab--in SciFinder CAS#299423-37-3
 * Teplizumab--in SciFinder CAS#876387-05-2
 * Tigatuzumab--INN, not in PubMed
 * Tilolizumab--not in PubMed or SciFinder
 * Tiratumumab--not in PubMed or SciFinder
 * Tocilizumab--in PubMed
 * Tolizumab--not in PubMed or SciFinder
 * Toralizumab--in SciFinder CAS#252662-47-8
 * Tralizumab--not in PubMed or SciFinder
 * Treglizumab--not in PubMed or SciFinder
 * Trelizumab--not in PubMed or SciFinder
 * Tremelimumab--in PubMed
 * Trilizumab--not in PubMed or SciFinder
 * Tritumumab--not in PubMed or SciFinder
 * Trixatumumab--not in PubMed or SciFinder
 * Tucotuzumab celmoleukin--in PubMed
 * Tucusituzumab--not in PubMed or SciFinder
 * Tuvirumab--in PubMed

U

 * Ubrelizumab--not in PubMed or SciFinder
 * Umavizumab--not in PubMed or SciFinder
 * Urtoxazumab--in SciFinder CAS#502496-16-4

V

 * Valtumumab--not in PubMed or SciFinder
 * Vapaliximab--in SciFinder CAS # 336801-86-6
 * Vepalimomab--in PubMed
 * Vedolizumab--USAN, not in PubMed
 * Vexatumumab--not in PubMed or SciFinder
 * Veltuzumab--USAN, in PubMed
 * Vimakinzumab--USAN under consideration
 * Visilizumab--in PubMed
 * Vontakinzumab--USAN under consideration
 * Votumumab--in SciFinder CAS#148189-70-2

X

 * Xalizumab--not in PubMed or SciFinder

Z

 * Zalutumumab--in SciFinder CAS#667901-13-5
 * Zanolimumab--in PubMed
 * Ziralimumab--not in PubMed or SciFinder
 * Zolimomab aritox--in PubMed
 * Zulizumab--not in PubMed or SciFinder